Active Ingredient: Norfloxacin
Prostate Cancer Prostatic Dis. Prostatitis: diagnosis and treatment. Am Fam Physician. Watson RA.
Chronic pelvic pain in men. ACP Medicine.
Nickel JC. Can Urol Assoc J. Chronic prostatitis: an infectious disease? Ann Behav Med.
J Urol. Church DL. This value appeared to be independent of the dosing interval or site of infection. Further investigations with murine thigh and lung infection models have been conducted with gatifloxacin, sitafloxacin and gemifloxacin.
Specifically, for S. One of the first reported studies, by Peloquin et al.
The study involved 50 patients with Gram-negative lower respiratory tract infections, half of whom had failed previous antimicrobial therapy.
Additionally, patients with trough concentrations exceeding the pathogen MIC were significantly more likely to show bacterial eradication. The killing rates were found to be considerably more rapid for P.
In total, these studies evaluated 313 adult patients, 134 of whom had clinical outcome determinations and an identified microorganism with a measured MIC of levofloxacin. The single clinical failure was an anomaly since the MIC of levofloxacin for this pathogen was 0.However, the development of resistance to this antibiotic represents a real challenge to laboratorians and clinicians. Treatment of invasive infections caused by.
Drusano, personal communication. Antimicrobials included in this analysis were cefmenoxime, imipenem, ceftazidime and ciprofloxacin. Limitations in the application of pharmacodynamic data There is significant agreement between pharmacodynamic data generated in vitro and those found through in vivo investigations; this correlation validates the clinical application of results obtained from in vitro pharmacodynamic models.
There are limited and conflicting data, however, regarding the generic predictability of these pharmacodynamic parameters for fluoroquinolones.